![Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials - London - 2017 - Cancer - Wiley Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials - London - 2017 - Cancer - Wiley](https://acsjournals.onlinelibrary.wiley.com/cms/asset/7ec0391a-b577-4b44-aac8-535a76de8de5/cncr30934-fig-0001-m.jpg)
Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials - London - 2017 - Cancer - Wiley
![Outcomes and endpoints in trials of cancer treatment: the past, present, and future - The Lancet Oncology Outcomes and endpoints in trials of cancer treatment: the past, present, and future - The Lancet Oncology](https://www.thelancet.com/cms/attachment/f10fa33d-cf21-48d9-862f-0a70a29890a5/gr1_lrg.jpg)
Outcomes and endpoints in trials of cancer treatment: the past, present, and future - The Lancet Oncology
![Endpoints in adjuvant trials: a systematic review of the literature in colon cancer and proposed definitions for future trials Marc E. Buyse. - ppt download Endpoints in adjuvant trials: a systematic review of the literature in colon cancer and proposed definitions for future trials Marc E. Buyse. - ppt download](https://images.slideplayer.com/32/10101651/slides/slide_13.jpg)
Endpoints in adjuvant trials: a systematic review of the literature in colon cancer and proposed definitions for future trials Marc E. Buyse. - ppt download
![Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis - The Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis - The](https://www.thelancet.com/cms/attachment/2cbba9be-95f0-4764-ad55-25b5e2074383/gr1.gif)
Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis - The
![Intermediate clinical endpoints: A bridge between progression‐free survival and overall survival in ovarian cancer trials - Matulonis - 2015 - Cancer - Wiley Online Library Intermediate clinical endpoints: A bridge between progression‐free survival and overall survival in ovarian cancer trials - Matulonis - 2015 - Cancer - Wiley Online Library](https://acsjournals.onlinelibrary.wiley.com/cms/asset/c787f601-c0f2-4f8b-b5f9-710b7ccfcbff/cncr29082-fig-0002-m.jpg)
Intermediate clinical endpoints: A bridge between progression‐free survival and overall survival in ovarian cancer trials - Matulonis - 2015 - Cancer - Wiley Online Library
![Estimating progression-free survival in patients with glioblastoma using routinely collected data | SpringerLink Estimating progression-free survival in patients with glioblastoma using routinely collected data | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs11060-017-2619-1/MediaObjects/11060_2017_2619_Fig1_HTML.gif)
Estimating progression-free survival in patients with glioblastoma using routinely collected data | SpringerLink
![Determining lines of therapy in patients with solid cancers: a proposed new systematic and comprehensive framework | British Journal of Cancer Determining lines of therapy in patients with solid cancers: a proposed new systematic and comprehensive framework | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41416-021-01319-8/MediaObjects/41416_2021_1319_Fig1_HTML.png)
Determining lines of therapy in patients with solid cancers: a proposed new systematic and comprehensive framework | British Journal of Cancer
![Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive](https://archive.cancerworld.net/wp-content/uploads/2015/10/Correlation-by-itself-does-not-imply-surrogacy.jpg)
Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive
![The Importance of Disease-Free Survival as a Clinical Trial Endpoint: A Qualitative Study Among Canadian Survivors of Lung Cancer | SpringerLink The Importance of Disease-Free Survival as a Clinical Trial Endpoint: A Qualitative Study Among Canadian Survivors of Lung Cancer | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40271-021-00552-w/MediaObjects/40271_2021_552_Fig1_HTML.png)
The Importance of Disease-Free Survival as a Clinical Trial Endpoint: A Qualitative Study Among Canadian Survivors of Lung Cancer | SpringerLink
![Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast. - ppt download Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast. - ppt download](https://images.slideplayer.com/30/9505354/slides/slide_4.jpg)
Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast. - ppt download
![Outcomes and endpoints in trials of cancer treatment: the past, present, and future - The Lancet Oncology Outcomes and endpoints in trials of cancer treatment: the past, present, and future - The Lancet Oncology](https://www.thelancet.com/cms/attachment/920222f6-291f-43c1-bae7-36f1bc4968b9/gr1.jpg)
Outcomes and endpoints in trials of cancer treatment: the past, present, and future - The Lancet Oncology
![JCM | Free Full-Text | Comprehensive Characterization of Human Lung Large Cell Carcinoma Identifies Transcriptomic Signatures with Potential Implications in Response to Immunotherapy JCM | Free Full-Text | Comprehensive Characterization of Human Lung Large Cell Carcinoma Identifies Transcriptomic Signatures with Potential Implications in Response to Immunotherapy](https://www.mdpi.com/jcm/jcm-11-01500/article_deploy/html/images/jcm-11-01500-g001.png)